No therapeutic advantage from didanosine (ddI) and hydroxyurea versus ddI alone in patients with HIV infection.
Simonelli
C
C
Comar
M
M
Zanussi
S
S
De Paoli
P
P
Tirelli
U
U
Giacca
M
M
D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D016896:Treatment Outcome; D014766:Viremia / Q000188:drug therapy; D015215:Zidovudine / Q000627:therapeutic use
D012367:RNA, Viral; D015215:Zidovudine; D016049:Didanosine; D006918:Hydroxyurea